InSysBio announces its participation in An Introduction to QSP, A UK QSP Network hybrid (in person/online) event which is to be held 17-20hrs 24th October 2024. Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will discuss the prediction of the first-in-human dose for T-cell engagers using mechanistic modelling.
October 24, 18.15-18.50
Oleg Demin Jr comments on the topic, "While the minimal anticipated biological effect level (MABEL) PK-driven approach is recommended for determining the safe clinical starting dose for T-cell engagers (TCE), this method can sometimes yield a low minimal recommended starting dose (MRSD) resulting in treatment of patients with sub-therapeutic doses and multiple dose escalations. Quantitative Systems Pharmacology (QSP) modeling is another approach to predict MRSD for TCE with potentially higher predictive power. In my presentation, I will discuss the advantages and challenges of mechanistic modeling for the selection of MRSD and compare it with the MABEL PK-driven approach using a case study on HPN536, a TCE targeting mesothelin."
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
← | August 2020 | → | ||||
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1
|
2
| |||||
3
1.
03 Aug 2020 16:00
InSysBio to share new data in frames of its Open Source QSP model of COVID-19
InSysBio has received a new set of results in framework of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|
4
|
5
|
6
1.
06 Aug 2020 17:51
InSysBio to update its Cytocon DB and to present version 1.2.6.6
InSysBio is glad to present Cytocon DB 1.2.6.6! Cytocon DB team has reviewed 39 articles to introduce new data. It should be outlined that the total number of concentrations within the Database has already exceeded 10 thousand!
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
20
1.
20 Aug 2020 17:18
InSysBio to present the new version of Immune Response Template
IRT 3.2.0 acquires new models and extended annotations
(Moscow – 20.08.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents the new version of its Immune Response Template (IRT). IRT is an efficient and useful tool to boost and facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas. By this point IRT has been developed into a fully-fledged database but InSysBio constantly goes further in its software advancement.
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|
31
|